Department of Medicine, Division of General Internal Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Curr Oncol. 2021 Jan 13;28(1):440-444. doi: 10.3390/curroncol28010046.
Prostate cancer can masquerade as just normocytic anemia and thrombocytopenia, thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or tumor lysis syndrome (TLS). We are reporting an intriguing case of metastatic prostate cancer which remained undiagnosed until the patient showed signs of tumor lysis syndrome (TLS), leading to urate nephropathy requiring urgent hemodialysis. Tumor lysis syndrome is an oncological emergency but an exceedingly rare complication in non-hematological malignancies, including prostate cancer. It is challenging to recognize features of TLS in a case such as this with an unknown diagnosis. In the case of an established diagnosis of malignancy, however, checking baseline renal function, uric acid, lactate dehydrogenase (LDH), potassium, and phosphate to monitor for TLS as well as considering urate lowering therapy can help prevent adverse outcomes.
前列腺癌可能表现为单纯正细胞性贫血和血小板减少症、血栓性血小板减少性紫癜(TTP)、溶血尿毒综合征(HUS)或肿瘤溶解综合征(TLS)。我们报告了一例转移性前列腺癌的病例,直到患者出现肿瘤溶解综合征(TLS)的迹象,导致尿酸肾病需要紧急血液透析,该病例才被诊断出来。肿瘤溶解综合征是一种肿瘤急症,但在包括前列腺癌在内的非血液系统恶性肿瘤中极为罕见。在这种情况下,识别 TLS 的特征具有挑战性,因为该病例的诊断尚不清楚。然而,对于已确诊的恶性肿瘤病例,检查基线肾功能、尿酸、乳酸脱氢酶(LDH)、钾和磷以监测 TLS 并考虑使用尿酸降低疗法有助于预防不良后果。